Jubilant Pharmo

{
  "main_header": {
    "sid": 525933,
    "name": "Jubilant Pharmo",
    "stock_name": "Jubilant Pharmo",
    "full_name": "Jubilant Pharmova Ltd",
    "name_url": "stocks-analysis/jubilant-pharmo",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "973.25",
    "chg": 15.75,
    "chgp": "1.64%",
    "dir": 1,
    "prev_price": "957.50",
    "mcapval": "15,798.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 530019,
    "symbol": "JUBLPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE700A01033",
    "curr_date": "Jun 23, 03:30 PM",
    "curr_time": "01:19 AM",
    "last_traded_at": "Jun 23, 03:30 PM IST",
    "bse_nse_vol": "2.73 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 23, 2026",
    "traded_date_str": "2026 06 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jubilant-pharmo-525933-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-4063222",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JubilantPharmov_mojoScore_4063222.png",
        "date": "2026-06-19 10:10:31",
        "description": "Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 10 April 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date analysis of the company’s standing in the market."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-4037528",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JubilantPharmov_mojoScore_4037528.png",
        "date": "2026-06-08 10:10:23",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-4037577",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JubilantPharmov_mojoScore_4037577.png",
        "date": "2026-06-07 10:10:20",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-4016585",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JubilantPharmov_mojoScore_4016585.png",
        "date": "2026-05-27 10:10:30",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jubilant Pharmova Ltd Reports Stabilised Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-ltd-reports-stabilised-quarterly-performance-amid-margin-pressures-4009711",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JubilantPharmov_fintrenddot_4009711.png",
        "date": "2026-05-25 08:00:11",
        "description": "Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, posted a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales reached a record high, profitability metrics showed contraction, reflecting margin pressures and operational challenges. The company’s recent financial trend has improved from negative to flat, yet the overall outlook remains cautious with a Sell mojo grade."
      },
      {
        "title": "Are Jubilant Pharmova Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jubilant-pharmova-ltd-latest-results-good-or-bad-4008902",
        "imagepath": "",
        "date": "2026-05-23 19:19:01",
        "description": "Jubilant Pharmova Ltd's latest financial results for Q4 FY26 present a complex picture of performance. The company reported a significant year-on-year revenue growth of 18.73%, reaching ₹2,290 crores, which marks the highest quarterly sales figure in recent history. This growth indicates a strong ability to expand market presence and capture business opportunities. However, the net profit for the same quarter was ₹119.40 crores, reflecting a decline of 22.27% compared to the previous year, which raises concerns about profitability.\n\nThe operating margin, excluding other income, was recorded at 14.93%, showing a sequential improvement from the previous quarter but a notable contraction of 310 basis points from the 18.03% achieved in Q4 FY25. This margin compression suggests challenges in maintaining pricing power and managing costs effectively in a competitive pharmaceutical landscape. Additionally, the comp..."
      },
      {
        "title": "Jubilant Pharmova Q4 FY26: Margin Pressure Clouds Strong Revenue Performance",
        "link": "https://www.marketsmojo.com/news/result-analysis/jubilant-pharmova-q4-fy26-margin-pressure-clouds-strong-revenue-performance-4007550",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JubilantPharmov_quaterlyResult_4007550.png",
        "date": "2026-05-22 21:46:34",
        "description": "Jubilant Pharmova Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹16,232 crores, reported a consolidated net profit of ₹119.40 crores for Q4 FY26, marking a dramatic 113.60% sequential jump from ₹55.90 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 22.27% decline from ₹153.60 crores in Q4 FY25, highlighting the uneven nature of the company's profitability trajectory. The stock currently trades at ₹1,005.75, down 0.54% on the day of this analysis."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-by-marketsmojo-3993865",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JubilantPharmov_mojoScore_3993865.png",
        "date": "2026-05-16 10:10:39",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-3975704",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JubilantPharmov_mojoScore_3975704.png",
        "date": "2026-05-05 10:10:53",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook."
      }
    ],
    "total": 403,
    "sid": "525933",
    "stock_news_url": "https://www.marketsmojo.com/news/jubilant-pharmova-525933"
  },
  "announcements": [
    {
      "caption": "Completion Of USFDA Inspection",
      "datetime": "19-Jun-2026",
      "details": "Completion of USFDA inspection",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "19-Jun-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 19 2026 for HSB Trustee Company Pvt Ltd and HS Trustee Company Pvt Ltd (jointly acting as trustee on behalf of Hari Shanker Bhartia Family Trust) & SPB Trustee Company Pvt Ltd and SS Trustee Company Pvt Ltd (jointly acting as trustee on behalf of Shyam Sunder Bhartia Family Trust)",
      "source": "BSE"
    },
    {
      "caption": "USFDA Inspection Update - Contract Manufacturing Facility At Montreal Canada",
      "datetime": "29-May-2026",
      "details": "USFDA update",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has declared <strong>500%</strong> dividend, ex-date: 24 Jul 26",
          "dt": "2026-07-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has announced <strong>1:5</strong> stock split, ex-date: 17 Mar 06",
          "dt": "2006-03-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jubilant Pharmova Ltd is Rated Sell

2026-06-19 10:10:31

Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 10 April 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date analysis of the company’s standing in the market.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-06-08 10:10:23

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-06-07 10:10:20

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-05-27 10:10:30

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jubilant Pharmova Ltd Reports Stabilised Quarterly Performance Amid Margin Pressures

2026-05-25 08:00:11

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, posted a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales reached a record high, profitability metrics showed contraction, reflecting margin pressures and operational challenges. The company’s recent financial trend has improved from negative to flat, yet the overall outlook remains cautious with a Sell mojo grade.

Read full news article

Are Jubilant Pharmova Ltd latest results good or bad?

2026-05-23 19:19:01

Jubilant Pharmova Ltd's latest financial results for Q4 FY26 present a complex picture of performance. The company reported a significant year-on-year revenue growth of 18.73%, reaching ₹2,290 crores, which marks the highest quarterly sales figure in recent history. This growth indicates a strong ability to expand market presence and capture business opportunities. However, the net profit for the same quarter was ₹119.40 crores, reflecting a decline of 22.27% compared to the previous year, which raises concerns about profitability. The operating margin, excluding other income, was recorded at 14.93%, showing a sequential improvement from the previous quarter but a notable contraction of 310 basis points from the 18.03% achieved in Q4 FY25. This margin compression suggests challenges in maintaining pricing power and managing costs effectively in a competitive pharmaceutical landscape. Additionally, the comp...

Read full news article

Jubilant Pharmova Q4 FY26: Margin Pressure Clouds Strong Revenue Performance

2026-05-22 21:46:34

Jubilant Pharmova Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹16,232 crores, reported a consolidated net profit of ₹119.40 crores for Q4 FY26, marking a dramatic 113.60% sequential jump from ₹55.90 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 22.27% decline from ₹153.60 crores in Q4 FY25, highlighting the uneven nature of the company's profitability trajectory. The stock currently trades at ₹1,005.75, down 0.54% on the day of this analysis.

Read full news article

Jubilant Pharmova Ltd is Rated Sell by MarketsMOJO

2026-05-16 10:10:39

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-05-05 10:10:53

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Read full news article

View All News